
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseases Highly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third …